EHA 2021 | The benefits of NGS in Waldenström’s macroglobulinemia
Steven Treon
• 1 Jun 2021
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, talks on the benefits of next-generation sequencing (NGS) in Waldenström’s macroglobulinemia (WM). NGS has identified MYD88 signaling mutations, which is seen in 95% of patients, as well as CXCR4 mutations present in around 40% of patients, pathing the way for treatment options to target aberrant MYD88 and CXCR4 signaling in WM. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Steven Treon, MD, PhD, has received research funding and consulting fees from Abbvie/Pharmacyclics, Janssen, Beigene, Eli Lilly and X4.
